GENALICE and Knome Form Strategic Partnership to Empower Rapid NGS Data Interpretation

WALTHAM, Mass. - Jan. 12, 2015 - PRLog -- Today GENALICE and Knome, Inc. USA jointly announced a strategic partnership to offer their products together as a turn-key solution for those using next-generation sequencing (NGS) data to interpret patients’ genomes. GENALICE MAP is an ultra-fast and highly accurate preprocessing solution for aligning and calling NGS data and seamlessly connects to Knome’s informatics and genomics interpretation system, the knoSYS® platform.

Stated CEO and President of Knome, Wolfgang Daum, “The GENALICE and Knome partnership came about in response to the reality that the amount of NGS data and its increasing usage requires processing and interpreting at an incredible pace. Wide-spread implementation of sequencing in the clinic toward the goal of precision medicine will only make this fact more apparent.”

While both products will continue to be offered separately, customers wanting to take advantage of the combined system can expect a reduction of NGS data bottlenecks, improved ability to annotate and interpret human genomes, and unprecedented control over their data from end-to-end.

Hans Karten, CEO of GENALICE, commented, “Whereas GENALICE MAP speeds up and improves the process of aligning and calling genomes, the knoSYS platform focuses on the annotation and interpretation piece. These two products complement each other beautifully in creating a workflow that eliminates many of the frustrations of wrangling NGS data today.”

About GENALICE

GENALICE is a highly innovative biomedical big data company, with global headquarters in the Netherlands. GENALICE designs and builds groundbreaking software solutions for ultra-fast, highly accurate and cost-effective DNA data processing and analysis on general-purpose hardware. With GENALICE MAP, it introduced the first Next-Generation Sequencing (NGS) data processing pipeline with true population power. By partnering with world-renowned research institutes and healthcare companies, GENALICE is committed to unlocking the potential of whole genome and exome sequencing for biomarker discovery and medical application. More information on GENALICE can be found at www.genalice.com.

About Knome, Inc.

Knome, Inc. is a leading provider of human genome interpretation systems and services. Knome provides tools and solutions that help researchers, drug developers, and clinicians determine the genetic basis of human disease and drug response. Designed to accelerate and industrialize the process of interpreting whole genomes, Knome’s big data technologies are helping to smooth the healthcare industry’s transition to molecular-based, precision medicine. For more information on Knome, visit www.knome.com.